- Home
- KITT vs HAE Comparison
KITT vs HAE Comparison
Compare KITT & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KITT
- HAE
- Stock Information
- Founded
- KITT 2014
- HAE 1971
- Country
- KITT United States
- HAE United States
- Employees
- KITT N/A
- HAE N/A
- Industry
- KITT Industrial Machinery/Components
- HAE Medical/Dental Instruments
- Sector
- KITT Industrials
- HAE Health Care
- Exchange
- KITT Nasdaq
- HAE Nasdaq
- Market Cap
- KITT N/A
- HAE 3.3B
- IPO Year
- KITT N/A
- HAE 1991
- Fundamental
- Price
- KITT $0.92
- HAE $67.66
- Analyst Decision
- KITT
- HAE Strong Buy
- Analyst Count
- KITT 0
- HAE 9
- Target Price
- KITT N/A
- HAE $99.78
- AVG Volume (30 Days)
- KITT 1.3M
- HAE 578.9K
- Earning Date
- KITT 05-14-2025
- HAE 05-08-2025
- Dividend Yield
- KITT N/A
- HAE N/A
- EPS Growth
- KITT N/A
- HAE 44.54
- EPS
- KITT N/A
- HAE 3.31
- Revenue
- KITT $1,508,374.00
- HAE $1,360,824,000.00
- Revenue This Year
- KITT $2,936.06
- HAE N/A
- Revenue Next Year
- KITT N/A
- HAE $6.76
- P/E Ratio
- KITT N/A
- HAE $20.46
- Revenue Growth
- KITT N/A
- HAE 3.96
- 52 Week Low
- KITT $0.82
- HAE $55.30
- 52 Week High
- KITT $14.85
- HAE $94.99
- Technical
- Relative Strength Index (RSI)
- KITT 43.38
- HAE 55.80
- Support Level
- KITT $0.91
- HAE $65.03
- Resistance Level
- KITT $1.02
- HAE $68.75
- Average True Range (ATR)
- KITT 0.06
- HAE 1.40
- MACD
- KITT -0.01
- HAE -0.24
- Stochastic Oscillator
- KITT 3.74
- HAE 44.35
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.